{"ok":true,"entity":{"id":"alnylam-pharmaceuticals","name":"Alnylam Pharmaceuticals","entityType":"company","officialName":"Alnylam Pharmaceuticals, Inc.","canonicalName":"Alnylam Pharmaceuticals","displayName":"Alnylam Pharmaceuticals","category":"RNAi治療薬を開発する米国のバイオ医薬品企業","shortDescription":"Alnylam Pharmaceuticalsは米国マサチューセッツ州ケンブリッジに本社を置き、RNAi（RNA干渉）治療薬を開発・販売するバイオ医薬品企業です。2026年7月30日発表の2026年第2四半期では、製品純売上高が11億7,210万ドル（前年同期比74%増）となり、通期のTTR領域売上見通しを下方修正しました（2026年10月時点）。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.alnylam.com/","updatedAt":"2026-10-20T07:08:03.177Z","secondaryClusters":[],"alias":["Alnylam","アルナイラム"],"searchKeywords":["アルナイラム","Alnylam","RNAi","siRNA","AMVUTTRA","アムヴトラ","ATTR-CM","RNA干渉","核酸医薬","ALNY"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}